Trial Profile
A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics After Multiple Oral Doses Of Pf-06700841 In Healthy Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Brepocitinib (Primary)
- Indications Alopecia areata; Plaque psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Pfizer
- 01 Dec 2022 Results (from 5 clinical trials; NCT02310750 NCT03236493 NCT03656952 NCT02969018 NCT02974868 ) assessing Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients published in the Clinical Pharmacology in Drug Development
- 23 Oct 2017 Status changed from recruiting to completed.
- 25 Sep 2017 Planned End Date changed from 13 Oct 2017 to 12 Oct 2017.